Shigeki Nanjo

Shigeki Nanjo

Auto-generated profile, based on publicly available information

Shigeki Nanjo

Department of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Science
Verified
Journal Article
Closed access
JQJeffrey J. Quinn
Jeffrey J. Quinn
MJMatthew G. Jones
Matthew G. Jones
RORoss A. Okimoto
Ross A. Okimoto
SNShigeki Nanjo
Shigeki Nanjo
MCMichelle M. Chan
Michelle M. Chan
JWJonathan S. Weissman
Jonathan S. Weissman
Following cancer through the body: The heterogeneity of mammalian tumors has been well documented, but it remains unknown how differences between individual cells lead to metastasis and spread throughout the body. Quinn et al. created a Cas9-based lineage tracer and used single-cell sequencing to generate phylogenies and follow the movement of metastatic human cancer cells implanted in the lung of a mouse xenograph model. Using this model, they found that within the same cell line, cancer cells exhibited diverse metastatic phenotypes. These subclones exhibited differential gene expression profiles, some of which were previously associated with metastasis. Science , this issue p. eabc1944

3 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
FHFranziska Haderk
Franziska Haderk
YCYu-Ting Chou
Yu-Ting Chou
LCLauren Cech
Lauren Cech
CFCelia Fernández-Méndez
Celia Fernández-Méndez
JYJohnny Yu
Johnny Yu
TBTrever Bivona
Trever Bivona
Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.

4 December 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
DCDeborah R. Caswell
Deborah R. Caswell
PGPhilippe Gui
Philippe Gui
MMManasi K. Mayekar
Manasi K. Mayekar
ELEmily K. Law
Emily K. Law
OPOriol Pich
Oriol Pich
CSCharles Swanton
Charles Swanton
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.

1 July 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SNShigeki Nanjo
Shigeki Nanjo
WWWei Wu
Wei Wu
NKNiki Karachaliou
Niki Karachaliou
CBCollin M. Blakely
Collin M. Blakely
JSJunji Suzuki
Junji Suzuki
TBTrever Bivona
Trever Bivona
Molecularly targeted cancer therapy has improved outcomes for patients with cancer with targetable oncoproteins, such as mutant EGFR in lung cancer. Yet, the long-term survival of these patients remains limited, because treatment responses are typically incomplete. One potential explanation for the lack of complete and durable responses is that oncogene-driven cancers with activating mutations of EGFR often harbor additional co-occurring genetic alterations. This hypothesis remains untested for most genetic alterations that co-occur with mutant EGFR. Here, we report the functional impact of inactivating genetic alterations of the mRNA splicing factor RNA-binding motif 10 (RBM10) that co-occur with mutant EGFR. RBM10 deficiency decreased EGFR inhibitor efficacy in patient-derived EGFR-mutant tumor models. RBM10 modulated mRNA alternative splicing of the mitochondrial apoptotic regulator Bcl-x to regulate tumor cell apoptosis during treatment. Genetic inactivation of RBM10 diminished EGFR inhibitor–mediated apoptosis by decreasing the ratio of (proapoptotic) Bcl-xS to (antiapoptotic) Bcl-xL isoforms of Bcl-x. RBM10 deficiency was a biomarker of poor response to EGFR inhibitor treatment in clinical samples. Coinhibition of Bcl-xL and mutant EGFR overcame the resistance induced by RBM10 deficiency. This study sheds light on the role of co-occurring genetic alterations and on the effect of splicing factor deficiency on the modulation of sensitivity to targeted kinase inhibitor cancer therapy.

3 June 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
ATAzusa Tanimoto
Azusa Tanimoto
TYTadaaki Yamada
Tadaaki Yamada
SNShigeki Nanjo
Shigeki Nanjo
STShinji Takeuchi
Shinji Takeuchi
HEHiromichi Ebi
Hiromichi Ebi
SYSeiji Yano
Seiji Yano
Alectinib is a new generation ALK inhibitor with activity against the gatekeeper L1196M mutation that showed remarkable activity in a phase I/II study with echinoderm microtubule associated protein-like 4 (EML4) - anaplastic lymphoma kinase (ALK) non-small cell lung cancer (NSCLC) patients. However, alectinib resistance may eventually develop. Here, we found that EGFR ligands and HGF, a ligand of the MET receptor, activate EGFR and MET, respectively, as alternative pathways, and thereby induce resistance to alectinib. Additionally, the heat shock protein 90 (Hsp90) inhibitor suppressed protein expression of ALK, MET, EGFR, and AKT, and thereby induced apoptosis in EML4-ALK NSCLC cells, even in the presence of EGFR ligands or HGF. These results suggest that Hsp90 inhibitors may overcome ligand-triggered resistance to new generation ALK inhibitors and may result in more successful treatment of NSCLC patients with EML4-ALK.

1 September 2017 in Lung Cancer
Verified
Journal Article
Closed access
AHAkito Hata
Akito Hata
NKNobuyuki Katakami
Nobuyuki Katakami
SNShigeki Nanjo
Shigeki Nanjo
COChiyuki Okuda
Chiyuki Okuda
RKReiko Kaji
Reiko Kaji
YHYukio Hirata
Yukio Hirata